Latest NKTR-262 REVEAL Results: Cursory A Bust, In Depth A Boon

|
About: Nektar Therapeutics (NKTR)
by: Chuck Gray
This article is exclusive for subscribers.
Chuck Gray
Special situations, event-driven, small-cap, healthcare
Summary

Nektar's March 1 postmarket analyst call at ASCO-SITC revealed data on four new evaluable cancer patients plus updates on the first seven evaluable patients treated with NKTR-262 plus bempegaldesleuken (NKTR-214).

The only change in patient status category was that one of the four new patients progressed to stable disease, but that result in isolation is highly misleading.

The side effects profile, the intratumoral and systemic immune system effects, the pharmacokinetic profile, the still escalating dosage of NKTR-262, and the pending addition of Opdivo all improve NKTR-262's prognosis.

On Friday, March 1, at 3 p.m. PT, Nektar Therapeutics (NKTR) conducted an analyst call presenting data on four new evaluable cancer patients, plus updates on the first seven evaluable REVEAL study patients